Research analysts at Roth Capital lowered their Q1 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Thursday, March 13th. Roth Capital analyst J.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...

Globus Medical GMED recently launched the COHERE ALIF Spacer, the first Porous PEEK interbody spacer for anterior lumbar interbody fusion (ALIF) surgery. Additionally, the company introduced Modulus ...

Globus Medical, Inc. (NYSE: GMED) has unveiled two groundbreaking additions to its anterior lumbar interbody fusion (ALIF) ...

Globus Medical GMED has outperformed the market over the past 10 years by 1.83% on an annualized basis producing an average ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Globus Medical (GMED – Research Report) yesterday and set a price target of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Globus Medical (GMED – Research Report) and ...

For the quarter ended December 2024, Globus Medical (GMED) reported revenue of $657.29 million, up 6.6% over the same period last year. EPS came in at $0.84, compared to $0.60 in the year-ago quarter.

StockNews.com lowered shares of Globus Medical (NYSE:GMED – Free Report) from a buy rating to a hold rating in a research ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...